Status:
RECRUITING
A Multicentre Observational Study to Assess Long-term Outcome of Participants in the EXCELLENT Clinical Trial
Lead Sponsor:
CellProthera
Conditions:
Acute Myocardial Infarction
Eligibility:
All Genders
18+ years
Brief Summary
The PERFECT study is an observational study designed to follow patients randomised in the EXCELLENT study (NCT02669810) for 10 years. The aim is to assess the long-term clinical outcomes for patients...
Eligibility Criteria
Inclusion criteria :
- Completion of the last visit in the EXCELLENT interventional clinical trial.
- Participation must be within 10 years after the randomization in the EXCELLENT trial
Exclusion criteria :
- Patients randomized to the ProtheraCytes® group who did not receive the product of the EXCELLENT Trial are excluded.
- Any other coexisting conditions that will preclude participation in the study or compromise ability to give informed consent
Key Trial Info
Start Date :
July 20 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 15 2034
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT06521047
Start Date
July 20 2024
End Date
March 15 2034
Last Update
September 25 2024
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
GHRMSA
Mulhouse, France, France, 68100
2
CHU DIJON Hôpital François Mitterrand 14 rue Gaffarel
Dijon, France, 21079
3
Institut Jacques Cartier
Massy, France
4
CHU Montpellier Arnaud-De-Villeneuve
Montpellier, France